Single-dose dalbavancin and patient satisfaction in an outpatient setting in the treatment of acute bacterial skin and skin structure infections
| Autor: | Patrick Gillard, Sailaja Puttagunta, Karthik Akinapelli, Katelyn R. Keyloun, Pedro L Gonzalez, Urania Rappo, Michael W. Dunne, Yan Liu |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male 0301 basic medicine Microbiology (medical) medicine.medical_specialty Adolescent Lipoglycopeptide Erythema 030106 microbiology Immunology Microbiology Young Adult 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Patient satisfaction Internal medicine Outpatients Clinical endpoint medicine Humans Immunology and Allergy 030212 general & internal medicine Abscess Aged Aged 80 and over business.industry Soft Tissue Infections Dalbavancin Skin Diseases Bacterial Middle Aged medicine.disease Anti-Bacterial Agents Regimen chemistry Patient Satisfaction Cellulitis Administration Intravenous Female Teicoplanin medicine.symptom business |
| Zdroj: | Journal of Global Antimicrobial Resistance. 17:60-65 |
| ISSN: | 2213-7165 |
| Popis: | Objectives Treatment of acute bacterial skin and skin structure infections (ABSSSIs) in the outpatient setting has potential advantages. We performed a subanalysis of outcomes for patients treated as outpatients versus inpatients with dalbavancin, a long-acting lipoglycopeptide, in a phase 3 clinical trial of ABSSSI. Methods The study was a double-blind trial of patients with ABSSSI randomised to receive dalbavancin 1500 mg intravenously as a single dose or two doses (1000 mg followed by 500 mg a week later). The primary endpoint was ≥20% reduction in erythema at 48–72 h after the start of therapy. Patient satisfaction and preference for antibiotic treatment and care setting were measured using the 10-item Skin and Soft Tissue Infection (SSTI) questionnaire at Day 14. Results A total of 698 patients were randomised (386 treated as outpatients and 312 as inpatients). Outpatients were more likely to be younger and to have major abscess or traumatic wound infection; inpatients were more likely to have cellulitis as the type of ABSSSI, to meet SIRS criteria and to have elevated plasma lactate at baseline. Efficacy and safety outcomes at 48–72 h, Days 14 and 28 were similar between patients treated in the outpatient and inpatient setting with either the single-dose or two-dose regimen. Outpatients reported significantly greater convenience and satisfaction with antibiotic treatment and care setting compared with inpatients (P Conclusion Single-dose dalbavancin is an effective treatment option for outpatients with ABSSSI and is associated with a high degree of patient treatment satisfaction and convenience. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect